50 related articles for article (PubMed ID: 10964715)
1. Design of a novel small peptide targeted against a tumor-specific receptor.
Campa MJ; Kuan CT; O'Connor-McCourt MD; Bigner DD; Patz EF
Biochem Biophys Res Commun; 2000 Aug; 275(2):631-6. PubMed ID: 10964715
[TBL] [Abstract][Full Text] [Related]
2. Identification of amino acid residues in PEPHC1 important for binding to the tumor-specific receptor EGFRvIII.
Hansen CL; Hansen PR; Pedersen N; Poulsen HS; Gillings N; Kjaer A
Chem Biol Drug Des; 2008 Oct; 72(4):273-8. PubMed ID: 18844673
[TBL] [Abstract][Full Text] [Related]
3. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
Lorimer IA; Wikstrand CJ; Batra SK; Bigner DD; Pastan I
Clin Cancer Res; 1995 Aug; 1(8):859-64. PubMed ID: 9816055
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library.
Denholt CL; Hansen PR; Pedersen N; Poulsen HS; Gillings N; Kjaer A
Biopolymers; 2009 Mar; 91(3):201-6. PubMed ID: 19107925
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
7. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
[TBL] [Abstract][Full Text] [Related]
9. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
10. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
[TBL] [Abstract][Full Text] [Related]
11. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
Yang B; Chen J; Zhang X; Cao J
Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
[TBL] [Abstract][Full Text] [Related]
12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation.
Ning Y; Zeineldin R; Liu Y; Rosenberg M; Stack MS; Hudson LG
Cancer Res; 2005 Oct; 65(20):9280-6. PubMed ID: 16230389
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation.
Pedersen MW; Pedersen N; Damstrup L; Villingshøj M; Sønder SU; Rieneck K; Bovin LF; Spang-Thomsen M; Poulsen HS
J Cell Biochem; 2005 Oct; 96(2):412-27. PubMed ID: 16075456
[TBL] [Abstract][Full Text] [Related]
15. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
[TBL] [Abstract][Full Text] [Related]
16. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
17. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
18. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor.
Shao H; Cheng HY; Cook RG; Tweardy DJ
Cancer Res; 2003 Jul; 63(14):3923-30. PubMed ID: 12873986
[TBL] [Abstract][Full Text] [Related]
20. A novel small peptide as a targeting ligand for receptor tyrosine kinase Tie2.
Wu X; Zhao R; Li Z; Yao M; Wang H; Han J; Qu S; Chen X; Qian L; Sun Y; Xu Y; Gu J
Biochem Biophys Res Commun; 2004 Mar; 315(4):1004-10. PubMed ID: 14985112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
